<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577967</url>
  </required_header>
  <id_info>
    <org_study_id>355/05</org_study_id>
    <secondary_id>HARECCTR0500020</secondary_id>
    <nct_id>NCT00577967</nct_id>
  </id_info>
  <brief_title>Gabapentin - A Solution to Uremic Pruritus?</brief_title>
  <official_title>Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      To investigate using the drug gabapentin to relieve the intense pruritic sensation associated
      with chronic renal failure patients undergoing peritoneal dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <completion_date type="Anticipated">March 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective measurement of reduction in pruritus</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Gabapentin in CAPD patients</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pruritus</condition>
  <condition>Uremia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Chinese male and female patients aged &gt; 18 undergoing CAPD for at least 3 months
             and able to read and understand Chinese

          -  Patients experiencing moderate to severe pruritis, defined as persistent,
             treatment-resistant pruritis considerably impairing sleep or daytime activity.
             Treatment resistance is defined as no or only partial resolvement of pruritis under
             current anti-pruritis treatment regimens such as anti-pruritis lotions and
             anti-histamines.

          -  Patients in stable clinical condition in terms of peritoneal dialysis and general
             health

          -  Patients able to understand and answer the SDS questionnaire

          -  Patients able to express the sensation of itchiness in the terms of the VAS and the
             SDS score

          -  Patients who are willing to give written informed consent and to participate in and
             comply with the study protocol

        Exclusion Criteria:

          -  Patients with a known history of pruritis or dermatologic disease antedating renal
             failure.

          -  Patients with skin disease other than the usual cutaneous findings of uraemia such as
             xerosis or ecchymosis.

          -  Patients under current treatment with systemic steroids

          -  Known history of allergy to Gabapentin

          -  Those patients already put on anti-convulsants

          -  Unable to give written informed consent for the study

          -  Pregnancy or female patients of child-bearing age who are unwilling to use
             contraception

          -  Poor drug compliance

          -  Known HIV positivity

          -  Active neoplastic disease

          -  Those who do not want to participate the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yui Pong Siu, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical and Geriatrics / Nephrology, Tuen Mun Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yui Pong Siu, Dr</last_name>
    <phone>(852) 2468 5750</phone>
    <email>maryvil@netivigator.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ka Hang Tong, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kay Tai Leung, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tze Hoi Kwan, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tak Cheung Au, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500020</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <last_update_submitted>July 6, 2010</last_update_submitted>
  <last_update_submitted_qc>July 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2010</last_update_posted>
  <keyword>Uremic pruritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

